Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

NCT04204850 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Recurrent Cancer
Liver Transplant

Interventions

DRUG: Cabozantinib

Sponsor

University Health Network, Toronto

Collaborators

[object Object]